|Quest Diagnostics Declares Quarterly Cash Dividend|
|MADISON, N.J., Aug. 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.45 per share, payable on October 18, 2017 to shareholders of record of Quest Diagnostics common stock on October 3, 2017.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived fro... ||08/18/17|
|Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook|
|- Second quarter revenues of $1.94 billion, up 1.9% on a reported basis and up 2.3% on an equivalent basis versus 2016.
- Second quarter diluted EPS of $1.37, flat on a reported basis from 2016; and $1.55 on an adjusted basis excluding amortization, up 15.7% from 2016. Excess tax benefit associated with stock-based compensation benefited diluted EPS by $0.10 in the quarter and increased $0.08 compared to 2016.
- Raises outlook for full year 2017 revenues, diluted EPS and cash provided by o... ||07/25/17|
|Quest Diagnostics Launches QHerit™, a Pan-Ethnic Genetic Screening Panel Aligned with New Medical Guidelines|
|QHerit Expanded Carrier Screen helps both women and men across multiple ethnicities identify risk of passing 22 genetic diseases to their children
MADISON, N.J., July 19, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of QHerit™, a new genetic screening service that provides women and men with insight into their genetic risk of passing on heritable disorders to their offspring.
|Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Precision Oncology Center of Excellence|
|MADISON, N.J., July 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company's first national center of excellence in precision diagnostics for oncology.
In connection with the transaction, Quest is now a pr... ||07/18/17|